A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of LCQ908 on Cardiovascular Risk
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2016
At a glance
- Drugs Pradigastat (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 20 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 30 May 2014 Planned End Date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.